Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3
Revenue Increased 113% During First Nine Months Of 2023
Executive Summary
Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.